140 related articles for article (PubMed ID: 12649674)
1. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary.
Klein WM; Kurman RJ
Int J Gynecol Pathol; 2003 Apr; 22(2):181-4. PubMed ID: 12649674
[TBL] [Abstract][Full Text] [Related]
2. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
3. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
4. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
Oliva E; Clement PB; Young RH
Adv Anat Pathol; 2000 Sep; 7(5):257-81. PubMed ID: 10976906
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
6. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma.
Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T
Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693
[TBL] [Abstract][Full Text] [Related]
7. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
8. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Oliva E; Young RH; Amin MB; Clement PB
Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
[TBL] [Abstract][Full Text] [Related]
9. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature.
Zafrakas M; Theodoridis TD; Zepiridis L; Venizelos ID; Agorastos T; Bontis J
Eur J Gynaecol Oncol; 2008; 29(3):264-6. PubMed ID: 18592792
[TBL] [Abstract][Full Text] [Related]
10. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
13. C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus.
Raspollini MR; Villanucci A; Amunni G; Paglierani M; Taddei A; Taddei GL
J Chemother; 2003 Feb; 15(1):81-4. PubMed ID: 12678420
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumors metastatic to the ovary: a report of five cases.
Irving JA; Lerwill MF; Young RH
Am J Surg Pathol; 2005 Jul; 29(7):920-6. PubMed ID: 15958857
[TBL] [Abstract][Full Text] [Related]
15. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement.
Lee CH; Hoang LN; Yip S; Reyes C; Marino-Enriquez A; Eilers G; Tao D; Chiang S; Fletcher JA; Soslow RA; Nucci MR; Oliva E
Mod Pathol; 2014 May; 27(5):751-7. PubMed ID: 24186140
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
17. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
18. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
Jeffers MD; Richmond JA; Macaulay EM
Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
[TBL] [Abstract][Full Text] [Related]
20. Uterine mesenchymal tumours: recent advances.
Momeni-Boroujeni A; Chiang S
Histopathology; 2020 Jan; 76(1):64-75. PubMed ID: 31846533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
